Contact Us For A Free Consultation (312) 238-9650 or (772) 242-9330

Investigating Potential Claims – Alliqua Biomedical Inc.

Are you concerned about your investment in Alliqua Biomedical Inc.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Arbitration claim against the brokerage firm that sold you the investment.

According to its website, Alliqua BioMedical (NASDAQ: ALQA) develops and manufactures electron-beam cross-linked sheet gels for customers that include manufacturers of medical devices, cosmeceuticals, and other commercial product applications.

According to SEC filings, Alliqua has filed several Regulation D Private Placements to raise capital from investors in New York, NY beginning in 2010. The company is formerly known as Alliqua Inc., and prior to that, Hepalife Technologies, Inc.

Investments such as these are typically sold by brokerage firms in exchange for a large up front commission. High fees can range from 7-10%, as well as additional “due diligence fees” that can range from 1-3%.

The problem with private placement investments such as Alliqua Inc. is that they typically involve a high degree of risk. They are also often sold as unregistered securities which lack the same regulatory oversight as more traditional investment products like stocks or bonds.

Are Private Placement Investments Suitable for you?

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for unsuitably recommending high-risk private placements, like Alliqua, to investors.